Trials / Recruiting
RecruitingNCT06620848
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in Patients With Advanced Biliary Tract Tumors.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-4642 monotherapy | HRS-4642 will be administrated per dose level in which the patients are assigned. |
| DRUG | HRS-4642 and adebrelimab combination therapy | HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned. |
Timeline
- Start date
- 2024-11-21
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2024-10-01
- Last updated
- 2025-04-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06620848. Inclusion in this directory is not an endorsement.